Viewing data from:

XELJANZ

NDA

TOFACITINIB CITRATE | N203214 | PF PRISM CV

2 strengths1 unique patent2 unique exclusivities

Patent Timeline

1 unique patent, 1 exclusivity by expiration date

Expired (1)TodayPED (+6 mo)Exclusivity

2026

2027

2028

Today

RE41783

Jun. 8, 2026

M-14

Aug. 21, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

10 cases on OB patents from PACER

Case	Court	Filed	Status	Judge
Pfizer Inc. et al v. Prinston Pharmaceutical Inc. 1:2025cv01202 1 patentANDA 209923tofacitinib citrate	D. Del.	2025-09-26	Terminated 2025-10-03	—
Pfizer Inc. et al v. Macleods Pharmaceuticals Ltd. 1:2025cv00632 1 patentANDA 219530tofacitinib citrate	D. Del.	2025-05-21	Terminated 2025-07-15	—
Pfizer Inc. et al v. Somerset Therapeutics LLC 1:2025cv00617 1 patentANDA 220137tofacitinib citrate	D. Del.	2025-05-16	Terminated 2025-10-01	—
Pfizer Inc. et al v. Annora Pharma Private Limited 1:2025cv00424 1 patentANDA 218437tofacitinib citrate	D. Del.	2025-04-04	Terminated 2025-05-13	—
Pfizer Inc. et al v. MSN Laboratories Private Ltd. 1:2022cv00746 3 patentsANDA 217299, 217298tofacitinib citrate	D. Del.	2022-06-06	Terminated 2022-08-24	—
Pfizer Inc. et al v. Aurobindo Pharma Ltd. et al 1:2021cv00022 2 patentsANDA 215356tofacitinib citrate	D. Del.	2021-01-11	Terminated 2022-05-06	—
Pfizer Inc. et al v. Ajanta Pharma Ltd. et al 1:2019cv00517 2 patentsANDA 212943tofacitinib	D. Del.	2019-03-15	Terminated 2020-06-05	—
Pfizer Inc. et al v. Prinston Pharmaceutical Inc. 1:2018cv00380 1 patentANDA 209923tofacitinib citrate	D. Del.	2018-03-09	Terminated 2019-02-07	—
Pfizer Inc. et al v. Breckenridge Pharmaceutical Inc. et al 1:2017cv01532 4 patentsANDA 209633tofacitinib citrate	D. Del.	2017-10-30	Terminated 2018-06-06	—
Pfizer Inc. et al v. Zydus Pharmaceuticals (USA) Inc. et al 1:2017cv00158 2 patentsANDA 209923tofacitinib citrate	D. Del.	2017-02-14	Terminated 2020-11-25	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

1 trial from ClinicalTrials.gov — 1 recruiting

Trial	Phase	Status	Sponsor	Enrollment	Dates
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease NCT07281456	Phase 2	Recruiting	National Institute of Dental and Craniofacial Research (NIDCR)	60	2025-12-18 → 2030-12-15

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Medicare Part D Spending

CMS annual spending data for Xeljanz (2023)

Total Spending

$280.0M

Total Claims

49,575

Beneficiaries

6,936

Avg Cost/Unit

$94.17

Spending Trend

$288.9M(2019)→$320.5M(2020)→$324.6M(2021)→$295.4M(2022)→$280.0M(2023)

YoY Change:+6.8%

5yr CAGR:+6.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain30 active DMFs1 inactive

29 active API suppliers hold Drug Master Files for this ingredient.

MSN LABORATORIES PRIVATE LTDTOFACITINIB CITRATE [ROUTE CODE - TT"]

DMF 277212013

ALIVUS LIFE SCIENCES LTDTOFACITINIB CITRATE

DMF 290022015

ZYDUS LIFESCIENCES LTDTOFACITINIB CITRATE

DMF 305312016

SHANDONG ANXIN PHARMACEUTICAL CO LTDTOFACITINIB CITRATE (NON-STERILE API)

DMF 305782016

SUN PHARMACEUTICAL INDUSTRIES LTDTOFACITINIB CITRATE

DMF 306172016

MICRO LABS LTDTOFACITINIB CITRATE

DMF 306212016

UNICHEM LABORATORIES LTDTOFACITINIB CITRATE

DMF 306542016

OLON SPATOFACITINIB CITRATE

DMF 306862016

YABAO PHARMACEUTICAL GROUP CO LTDTOFACITINIB CITRATE

DMF 320352019

BEIJING MESOCHEM TECHNOLOGY CO LTDTOFACITINIB CITRATE

DMF 324452018

APOTEX INCTOFACITINIB CITRATE

DMF 325472018

DELMAR CHEMICALS INCTOFACITINIB CITRATE

DMF 333322018

BEIJING SJAR TECHNOLOGY DEVELOPMENT CO LTDTOFACITINIB CITRATE

DMF 341562019

ZHEJIANG AUSUN PHARMACEUTICAL CO LTDTOFACITINIB CITRATE

DMF 351522020

PHARMABLOCK PHARMACEUTICALS (ZHEJIANG) CO LTDTOFACITINIB CITRATE

DMF 357132021

CHANGZHOU PHARMACEUTICAL FACTORYTOFACITINIB CITRATE

DMF 357462021

AURORE LIFE SCIENCES PRIVATE LTDTOFACITINIB CITRATE

DMF 358442021

METROCHEM API PRIVATE LTDTOFACITINIB CITRATE

DMF 359762021

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDTOFACITINIB CITRATE

DMF 362972021

HONOUR LAB LTDTOFACITINIB CITRATE

DMF 365422022

MATRIX PHARMACORP PRIVATE LTDTOFACITINIB CITRATE

DMF 365762021

INTAS PHARMACEUTICALS LTDTOFACITINIB CITRATE

DMF 371562022

DR REDDYS LABORATORIES LTDTOFACITINIB CITRATE

DMF 371642022

HUNAN WARRANT CHIRAL PHARMACEUTICAL CO LTDTOFACITINIB CITRATE

DMF 374712022

LEE PHARMA LTDTOFACITINIB CITRATE

DMF 374962022

CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDTOFACITINIB CITRATE

DMF 375322022

MACLEODS PHARMACEUTICALS LTDTOFACITINIB CITRATE

DMF 385232023

METROCHEM API PRIVATE LTDTOFACITINIB CITRATE (PAI)

DMF 389942023

YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTDTOFACITINIB CITRATE NON-STERILE DRUG SUBSTANCE

DMF 400262024

SHANDONG JINCHENG KUNLUN PHARMACEUTICAL CO LTDTOFACITINIB CITRATE

DMF 413642025

SINTENOVO SA DE CVInactiveTOFACITINIB CITRATE

DMF 305542016

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

25 letters from Drugs@FDA

Date	Submission	Document
Mar 9, 2026	SUPPL -41	View Letter (PDF)
Oct 20, 2025	SUPPL -39	View Letter (PDF)
Feb 25, 2025	SUPPL -38	View Letter (PDF)
Sep 30, 2024	SUPPL -36	View Letter (PDF)
May 20, 2024	SUPPL -34	View Letter (PDF)
Dec 16, 2021	SUPPL -28	View Letter (PDF)
Dec 6, 2021	SUPPL -31	View Letter (PDF)
Sep 29, 2020	SUPPL -26	View Letter (PDF)
Dec 13, 2019	SUPPL -25	View Letter (PDF)
Sep 12, 2019	SUPPL -23	View Letter (PDF)
Jul 26, 2019	SUPPL -24	View Letter (PDF)
Oct 23, 2018	SUPPL -20	View Letter (PDF)
Aug 20, 2018	SUPPL -21	View Letter (PDF)
May 31, 2018	SUPPL -18	View Letter (PDF)
Dec 15, 2017	SUPPL -17	View Letter (PDF)
Feb 9, 2016	SUPPL -13	View Letter (PDF)
Dec 23, 2015	SUPPL -11	View Letter (PDF)
Jun 24, 2015	SUPPL -10	View Letter (PDF)
Feb 17, 2015	SUPPL -8	View Letter (PDF)
May 8, 2014	SUPPL -7	View Letter (PDF)
Mar 28, 2014	SUPPL -5	View Letter (PDF)
Feb 25, 2014	SUPPL -4	View Letter (PDF)
Nov 20, 2013	SUPPL -2	View Letter (PDF)
Nov 12, 2013	SUPPL -6	View Letter (PDF)
Nov 7, 2012	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 5MG BASE

RLDAB

1 patent2 exclusivities▴

TABLET;ORAL | Approved: Nov 6, 2012

Patents (1)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
RE41783	Dec 8, 2025PED: Jun 8, 2026	PED	Yes	—	—	—

Exclusivities (2)

Code	Date	Status
M-14	Feb 21, 2028	Active
PED	Aug 21, 2028	Active

#002 — EQ 10MG BASE

RLDAB

1 patent0 exclusivities▾

TABLET;ORAL | Approved: May 30, 2018